- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.07. | Sharp Therapeutics Corp (2): Sharp Therapeutics closes $1.36-million financing | 1 | Stockwatch | ||
| SHARP THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 29.07. | Sharp Therapeutics Corp.: Sharp Therapeutics Announces Closing of Non-Brokered Private Placement | 366 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - July 29, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it has... ► Artikel lesen | |
| 21.07. | Sharp Therapeutics Corp.: Sharp Therapeutics Corp. Announces Results from Annual Meeting of Shareholders | 422 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - July 21, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) ("Sharp" or the "Company"), a pre-clinical biotechnology company developing... ► Artikel lesen | |
| 16.07. | Sharp Therapeutics Corp (2): Sharp Therapeutics arranges $1.36M private placement | 2 | Stockwatch | ||
| 15.07. | Sharp Therapeutics Corp.: Sharp Therapeutics Announces Non-Brokered Private Placement and Provides Operational Update | 265 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - July 15, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it is... ► Artikel lesen | |
| 30.06. | Sharp Therapeutics Corp.: Sharp Therapeutics Announces Filing of Amended and Restated Management Information Circular and New Annual Meeting Date | 493 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - June 30, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") announces that its annual meeting... ► Artikel lesen | |
| 09.06. | Sharp Therapeutics Corp (2): Sharp Therapeutics debenture private placement | 1 | Stockwatch | ||
| 28.05. | Sharp Therapeutics Presents New Preclinical Data Supporting Novel Small-Molecule Therapeutic Approach for Niemann-Pick Disease Type C | 3 | GlobeNewswire (USA) | ||
| 18.04. | Sharp Therapeutics Corp (2): Sharp Therapeutics closes $1.55M (U.S.) note financing | 1 | Stockwatch | ||
| 18.04. | Sharp Therapeutics Corp.: Sharp Therapeutics Corp. Announces Fourth Quarter 2025 Results, Closing of Convertible Note Offering and Adoption of Semi-Annual Reporting | 839 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - April 17, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") announces the release of its annual... ► Artikel lesen | |
| 11.04. | Sharp Therapeutics Corp (2): Sharp seeks replacement compound for Gaucher, GBA1 | 1 | Stockwatch | ||
| 11.04. | Sharp Therapeutics Corp (2): Sharp closes $200k (U.S.) fourth tranche of placement | 3 | Stockwatch | ||
| 10.04. | Sharp Therapeutics Corp.: Sharp Therapeutics Updates on '901 for Gaucher and GBA1 Parkinson's and Platform Programs | 977 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - April 10, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") announces that following longer-term... ► Artikel lesen | |
| 10.04. | Sharp Therapeutics Corp.: Sharp Therapeutics Announces Closing of Fourth Tranche of Unsecured Convertible Note Offering | 1.022 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - April 10, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it... ► Artikel lesen | |
| 03.04. | Sharp Therapeutics Corp (2): Sharp Therapeutics closes third tranche of offering | 1 | Stockwatch | ||
| 02.04. | Sharp Therapeutics Corp.: Sharp Therapeutics Announces Closing of Third Tranche of Unsecured Convertible Note Offering | 955 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - April 2, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it has... ► Artikel lesen | |
| 14.03. | Sharp Therapeutics Corp (2): Sharp Therapeutics closes second tranche of placement | 2 | Stockwatch | ||
| 13.03. | Sharp Therapeutics Corp.: Sharp Therapeutics Announces Closing of Second Tranche of Unsecured Convertible Note Offering | 879 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - March 13, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it... ► Artikel lesen | |
| 28.02. | Sharp Therapeutics Corp (2): Sharp Therapeutics closes first tranche of financing | 3 | Stockwatch | ||
| 27.02. | Sharp Therapeutics Corp.: Sharp Therapeutics Announces Closing of First Tranche of Unsecured Convertible Note Offering | 635 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - February 27, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that... ► Artikel lesen |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AMYLYX PHARMACEUTICALS | 30,370 | +41,72 % | Amylyx Pharmaceuticals Comes Closer to Potentially Delivering First Treatment for Weight Loss Surgery-Related Low Suger Level | ||
| QIAGEN | 37,415 | +0,93 % | Qiagen überzeugt mit Zahlen, Micron ohne neuen Ausbruch und AST SpaceMobile verfehlt die Erwartungen - BÖRSE TO GO | Ein wenig wurde an den Börsen auch zu Beginn der neuen Woche noch aufgrund nachlassender Zinssorgen aufgeatmet. Begleitet wurde dies allerdings von eher unschönen Neuigkeiten aus Nahost, welche prompt... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 134,56 | -0,02 % | This Apogee Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday | ||
| PRAXIS PRECISION MEDICINES | 373,61 | -0,61 % | Raymond James raises Praxis Precision Medicines price target on pipeline outlook | ||
| EVOTEC | 3,404 | -0,82 % | Evotec Aktie: Lebenszeichen aus der Totenstille - wer kauft denn da? | Die auffällige Ruhe bei der Evotec Aktie, die im letzten 4investors.de-Chartcheck im Mittelpunkt stand, ist durchbrochen. Damals lautete die Frage, ob jemand leise in die Totenstille der Biotechnologie-Aktie... ► Artikel lesen | |
| TANGO THERAPEUTICS | 25,540 | +1,05 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 71,11 | +0,70 % | Tarsus Pharmaceuticals, Inc: Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position | Adds a potential blockbuster opportunity with gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt disease, one of... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 45,040 | +2,27 % | Edgewise Therapeutics Reports Second Quarter 2026 Financial Results | - Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) -
- ... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 59,73 | +0,33 % | Barclays startet Coverage für Enliven Therapeutics mit "Overweight" und Kursziel von 78 Dollar | ||
| BEAM THERAPEUTICS | 26,645 | -1,55 % | Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD) | Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026 Dosing Complete for All Adult and Adolescent Patients... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 120,78 | -0,52 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| DISC MEDICINE | 80,28 | +0,29 % | Disc Medicine Inc: Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update | Completed Type A meeting with the FDA on bitopertin and aligned that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response; topline data expected in Q4 2026Launched Expanded... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 12,710 | -0,55 % | Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)'s Cancer Drug Partnership Create a New Treatment Standard? | ||
| ERASCA | 18,490 | +1,15 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen | |
| BB BIOTECH | 58,00 | +0,69 % | Edison Investment Research Limited: Edison issues report on BB Biotech (BION) | Edison Investment Research Limited
Edison issues report on BB Biotech (BION) 28-Jul-2026 / 14:20 GMT/BST
The issuer is solely responsible for the content of this announcement.
... ► Artikel lesen |
SHARP THERAPEUTICS CORP gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHARP THERAPEUTICS CORP finden Sie auf Wallstreet Online.